source
- Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trialLicensed from Kelun-Biotech, Merck’s TROP2-targeting antibody drug conjugate sac-TMT improved overall survival in advanced gastroesophageal cancer while missing on two secondary endpoints.BioSpace · 3h ago↗ source
- FDA approves Regeneron's first siRNA therapy for generalized myasthenia gravisThe FDA has granted approval for Regeneron's siRNA drug Livsayis (cemdisiran) for adult patients with generalized myasthenia gravis who are positive for anti‑acetylcholine receptor antibodies. Thi…